Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content


FULL TITLE

Oxford Pre-Cancerous Lymphoproliferative Disorders: Analysis and Interception study 

Chief Investigator: Professor Anna SchuhOxPLoreD_Logo_V1.0_Apr2018.jpg

Sponsor: University of Oxford                                 

 

STUDY DESIGN

OxPLoreD is an observational cohort study

 

STUDY POPULATION

The study targets 3 groups of early lymphoproliferative disorders:

  1. Monoclonal B-cell lymphocytosis and asymptomatic Chronic Lymphocytic Leukaemia
  2. IgM Monoclonal gammopathy and asymptomatic Waldenström’s macroglobulinaemia
  3. IgA or IgG Monoclonal gammopathy and smouldering myeloma  

STUDY STATUS

STUDY STATUS

Open for recruitment

TARGET RECRUITMENT

1650 participants Total

CURRENT RECRUITMENT

None

PARTICIPATING SITE

Churchill Hospital – Oxford University Hospital Trust

 

INCLUSION CRITERIA

InclusionCriteria.jpg

EXCLUSION CRITERIA

OxPloredExclusionCriteria.jpg

PRIMARY OBJECTIVE

  • To identify the clinical, genomic and immunological predictive markers of progression to malignant disease

SECONDARY OBJECTIVES

  • To assess Quality of Life of patients with pre-cancerous lymphoid conditions
  • To study other clinical complications associated with pre-malignancy (infection, bony fractures, thrombosis and deaths not to progression to lymphoid cancers)
  • To establish evidence-based guidance for monitoring and follow-up of patients with pre-cancerous conditions

EXPLORATORY OBJECTIVES

  • To identify novel surrogate markers of cure
  • To gather feasibility data in this subgroup at high-risk of progression to inform a future early intervention trial

 

KEY DATES

Open to recruitment: July 2019

End of recruitment: May 2024

End of Trial: May 2026

 

DATA SUBMISSION

Data submission for this trial is via electronic submission of the data into OpenClinica

 

CONTACT US

OxPLoreD Trial office

Tel: +44 (0)1865 617087

Email: octo-oxplored@oncology.ox.ac.uk

 

 

 

On this page